Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06295809 |
| Consolidated Lead Sponsor | Merck & Co. |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II/III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 46 participants (ACTUAL) |
| Registered Start Date | 2024-04-18 |
| WhyStopped Classification | Strategic / Business / Sponsor Decision |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| USC Norris Comprehensive Cancer Center and Keck Medicine | Los Angeles, CA | Open Hospital Dossier -> |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | Open Hospital Dossier -> |
| Emory Winship Cancer Institute | Atlanta, GA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.